1. Home
  2. ASTL vs ALT Comparison

ASTL vs ALT Comparison

Compare ASTL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Algoma Steel Group Inc.

ASTL

Algoma Steel Group Inc.

HOLD

Current Price

$4.14

Market Cap

481.8M

Sector

Industrials

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.08

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTL
ALT
Founded
1902
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
481.8M
573.8M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
ASTL
ALT
Price
$4.14
$3.08
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
1.3M
4.2M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
1.12%
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$23.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$3.02
$2.56
52 Week High
$5.90
$6.44

Technical Indicators

Market Signals
Indicator
ASTL
ALT
Relative Strength Index (RSI) 47.81 51.70
Support Level $4.06 $2.80
Resistance Level $4.60 $3.09
Average True Range (ATR) 0.30 0.13
MACD -0.03 0.00
Stochastic Oscillator 19.40 57.32

Price Performance

Historical Comparison
ASTL
ALT

About ASTL Algoma Steel Group Inc.

Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: